Cardiovascular

Akura Medical is developing the Katana saline-jet thrombectomy system for pulmonary embolism, now in the QUADRA-PE trial under an FDA IDE.

Develops Pulse IVL, an intravascular lithotripsy system that uses pulsed pressure waves generated from carbon dioxide inside a balloon catheter to fracture calcium in arteries.

Makes the Hotwire radiofrequency guidewire, which crosses the atrial septum and then serves as the working wire for left heart procedures such as atrial fibrillation ablation. Johnson and Johnson agreed to acquire the company in April 2026.

Biobeat makes a chest-worn patch that measures blood pressure and other vitals without a cuff, cleared for 24-hour ambulatory monitoring.

Bunkerhill Health develops FDA-cleared AI algorithms that find cardiovascular and bone disease on imaging and ECGs ordered for other reasons. Hospitals run them through its Carebricks platform.

Builds a chest-worn cardiac sensor and AI software that noninvasively estimate hemodynamic pressures for heart failure management.

Develops AI software that quantifies coronary inflammation and plaque from coronary CT angiography to predict cardiac risk. University of Oxford spinout with a U.S. office in Stamford, Connecticut.

Developing a catheter that performs targeted nerve ablation in the upper abdomen to treat chronic heart failure, with a probe designed to limit damage to surrounding tissue.

Develops bioabsorbable vascular closure devices for femoral arterial access sites after catheter procedures.

Makes the Hēlo Thrombectomy System, a catheter that combines aspiration with mechanical clot disruption for venous thromboembolism. Cleared under K252956 in December 2025.

Builds PlaqueIQ, FDA-cleared software that quantifies plaque composition from coronary CT angiography, and a BioIntegrated FFR-CT product under FDA review.

Developed the NEXUS off-the-shelf stent graft for endovascular repair of the aortic arch. Distributed in Europe by Artivion, which held an option to acquire the company on FDA approval.

Makes HeartWatch, a wearable for continuous at home heart monitoring with an emergency contact function.

Inquis Medical makes the Aventus aspiration thrombectomy system with blood reinfusion and tissue sensing for deep vein thrombosis and pulmonary embolism.

Develops the Trilogy transcatheter heart valve, approved in the U.S. in 2026 for severe aortic regurgitation. Backed by Bain Capital Life Sciences, Andera Partners and Valiance.

Jupiter Endovascular builds the Vertex catheter system, which uses pressurized transforming fixation to hold position in the pulmonary arteries for clot removal.

Makes the Globe Pulsed Field System for atrial fibrillation ablation. Its catheter carries 122 individually selectable electrodes, so mapping and ablation run from the same device.

Builds spine and orthopedic implants from molybdenum-rhenium alloys, with 24 510(k) clearances, and is developing SIEGEL, a nickel-free balloon-expandable TAVR valve in the STAR trial. Boston Scientific owns about 34% after a $1.5B investment in May 2026.

Okami Medical makes the LOBO braided vascular occluder and Sendero delivery catheters for peripheral embolization.

Makes aspiration and access catheters for mechanical thrombectomy in ischemic stroke, including the 0.088-inch Millipede88.

Makes the Minima Stent System, a balloon-expandable growth stent for pulmonary artery stenosis and coarctation of the aorta in neonates and infants. Approved under PMA P240003 in August 2024.

Building phone based monitoring and management for heart rhythm medications, founded by electrophysiologist and bioengineer Rachita Navara.

Developing a pressure driven perfusion system that holds vascular pressure during procedures that obstruct blood flow, aimed at acute limb ischemia. Built inside Sofinnova's MD Start accelerator.

Makes an adhesive sensor that monitors blood pressure continuously, validated first in operating room settings.

Makes a bioabsorbable wrap placed around a blood vessel during dialysis access and bypass surgery to reduce the chance the connection fails.

inQB8 Medical Technologies spinout developing TVARC, a transcatheter valved aortic root conduit for aortic root and ascending aortic disease. Preparing for first-in-human use.